@article {1887,
	title = {Vancomycin, Linezolid, and Ceftaroline In vitro Activity Against Methicillin susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) Isolates},
	journal = {Pharmacognosy Journal},
	volume = {14},
	year = {2022},
	month = {October 2022},
	pages = {671-674},
	type = {Research Article},
	chapter = {671},
	abstract = {<p class="rtejustify">MRSA-infected patients incur twice as many costs as MSSA-infected patients. Vancomycin, Linezolid, and, most recently, Ceftaroline are among Indonesia{\textquoteright}s several MRSA treatment options. Therefore, we sought to assess the efficacy of these three medications. The investigation was done at the Dr. Soetomo General Academy Hospital{\textquoteright}s Clinical Microbiology Laboratory in Surabaya. The bacterium ATCC 25923, ATCC 43300, MSSA clinical isolate, and MRSA clinical isolate of <em>Staphylococcus aureus</em> were studied. Vancomycin, Linezolid, and ceftaroline were administered at respective dosages of 1 MIC, 2 MIC, and 4 MIC. In addition, a time-kill test was performed, which consisted of counting the growth of colonies on solid media, generating a time-kill curve, and determining MBC. The number of colonies in the antibiotic groups at 4, 6, and 8 hours varied significantly, according to the study (Vancomycin, Linezolid, and Ceftaroline). In contrast, the number of bacteria did not differ significantly between Vancomycin and Linezolid until the fourth hour. Except at 6 and 24 hours, neither Vancomycin nor Ceftaroline significantly altered the number of bacteria. There was a significant difference in the number of colonies between Ceftaroline and Linezolid at 4, 6, and 8 hours. Vancomycin, Linezolid, and Ceftaroline against MSSA and MRSA isolates vary greatly.</p>
},
	keywords = {MRSA, MSSA, Time-kill curve},
	doi = {10.5530/pj.2022.14.152},
	author = {Eny Purwoningsih and Pepy Dwi Endraswari and Agung Dwi Wahyu Widodo}
}
